Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.
Camille C. Gunderson, MD
Advertisement
Articles by Camille C. Gunderson, MD
Camille C. Gunderson, MD, discusses the phase III open-label GOG-252 trial in advanced ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Gunderson on the GOG-252 Trial in Advanced Ovarian CancerSeptember 19th 2019
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5